Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

8.0%

2 terminated out of 25 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results60% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (1)
P 1 (13)
P 2 (9)

Trial Status

Recruiting10
Active Not Recruiting5
Unknown4
Completed3
Terminated2
Withdrawn1

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT04483778Phase 1Active Not Recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04897321Phase 1Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT05918640Phase 1Recruiting

Lurbinectedin in FET-Fused Tumors

NCT06625190Phase 1Recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT01946529Phase 2Active Not RecruitingPrimary

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

NCT06709495Phase 1Recruiting

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT03967834Not ApplicableRecruiting

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

NCT04690374RecruitingPrimary

Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor

NCT07328425Phase 2RecruitingPrimary

Clinical Study in Patients With DSRCT

NCT06849986Phase 2Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT04145349Phase 1Active Not RecruitingPrimary

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT03618381Phase 1Active Not Recruiting

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT06277154Phase 2Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT04022213Phase 2Active Not RecruitingPrimary

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT04530487Phase 2TerminatedPrimary

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

NCT01125449Phase 2Withdrawn

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

NCT04095221Phase 1CompletedPrimary

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

NCT06456359Phase 2RecruitingPrimary

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

NCT04901806Phase 1Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

NCT03600649Phase 1Unknown

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Scroll to load more

Research Network

Activity Timeline